PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9726984-5 1998 2"-Deoxycoformycin, an adenosine deaminase (EC 3.5.4.4) inhibitor, increased the potency of adenosine 5-fold, suggesting that the effectiveness of adenosine as an autophagy inhibitor was curtailed by its intracellular deamination. Pentostatin 0-18 adenosine deaminase Rattus norvegicus 23-42 16542004-2 2006 This in vivo study explores this prodrug conversion in rats and inhibition by a potent adenosine deaminase inhibitor, 2"-deoxycoformycin. Pentostatin 118-136 adenosine deaminase Rattus norvegicus 87-106 10820140-6 2000 The objectives of the study were to determine whether the ADA inhibitors 2"-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine were capable of achieving a substantial and selective inhibition of gut wall activation of 6AC, and to determine whether the systemic concentrations of 6AC would be thus increased. Pentostatin 73-91 adenosine deaminase Rattus norvegicus 58-61 12771621-1 2003 OBJECTIVE: We sought to determine the potential usefulness of 2"-deoxycoformycin (pentostatin), an inhibitor of adenosine deaminase, as a postinsult, or prophylactic treatment for systemic inflammatory response syndrome resulting from fecal peritonitis. Pentostatin 62-80 adenosine deaminase Rattus norvegicus 112-131 12771621-1 2003 OBJECTIVE: We sought to determine the potential usefulness of 2"-deoxycoformycin (pentostatin), an inhibitor of adenosine deaminase, as a postinsult, or prophylactic treatment for systemic inflammatory response syndrome resulting from fecal peritonitis. Pentostatin 82-93 adenosine deaminase Rattus norvegicus 112-131 9013123-1 1997 Puromycin aminonucleoside (PAN) toxicity was totally inhibited in the rat in vivo and in cultured glomerular epithelial cells (GECs) in vitro using the adenosine deaminase (ADA) inhibitor, 2"-deoxycoformycin (DCF). Pentostatin 189-207 adenosine deaminase Rattus norvegicus 173-176 9399998-12 1997 Also, their potential for immunotoxicity, if any, appears to be transient in nature, representing an important clinical advantage compared with tight-binding ADA inhibitors such as deoxycoformycin. Pentostatin 181-196 adenosine deaminase Rattus norvegicus 158-161 9210198-9 1997 DCF pre-treatment inhibited brain tissue ADA, abolishing the prodrug effect, and enhancing F-ddA concentrations in both brain parenchyma (5x) and CSF (6x). Pentostatin 0-3 adenosine deaminase Rattus norvegicus 41-44 9572907-8 1998 Co-perfusion of the potent, hydrophilic ADA inhibitor DCF (Ki = 0. Pentostatin 54-57 adenosine deaminase Rattus norvegicus 40-43 9013123-1 1997 Puromycin aminonucleoside (PAN) toxicity was totally inhibited in the rat in vivo and in cultured glomerular epithelial cells (GECs) in vitro using the adenosine deaminase (ADA) inhibitor, 2"-deoxycoformycin (DCF). Pentostatin 209-212 adenosine deaminase Rattus norvegicus 173-176 9013123-2 1997 DCF completely inhibited ADA activity in glomeruli and protected against the development of PAN nephrosis; the 24-h urinary protein excretion of treated rats compared with controls (PAN rats) 9 days after PAN injection was 16 +/- 2 mg and 524 +/- 55 mg, respectively (p < .01). Pentostatin 0-3 adenosine deaminase Rattus norvegicus 25-28 7640871-2 1995 2"-Deoxycoformycin (Pentostatin, DCF) irreversibly inhibits ADA and therefore has been suggested as an immunosuppressive drug. Pentostatin 0-18 adenosine deaminase Rattus norvegicus 60-63 8846098-3 1995 An inhibitor of adenosine deaminase (deoxycoformycin, DCF) in combination with an inhibitor of adenosine transport (dilazep, DLZP) at a dose that did not affect levels of endogenous adenosine, potentiated NMDA-induced increases in adenosine levels to 426% of contralateral striata. Pentostatin 37-52 adenosine deaminase Rattus norvegicus 16-35 7640871-2 1995 2"-Deoxycoformycin (Pentostatin, DCF) irreversibly inhibits ADA and therefore has been suggested as an immunosuppressive drug. Pentostatin 20-31 adenosine deaminase Rattus norvegicus 60-63 7640871-2 1995 2"-Deoxycoformycin (Pentostatin, DCF) irreversibly inhibits ADA and therefore has been suggested as an immunosuppressive drug. Pentostatin 33-36 adenosine deaminase Rattus norvegicus 60-63 7891860-5 1994 The effects of adenosine deaminase were prevented by the specific inhibitor, deoxycoformycin (30 microM). Pentostatin 77-92 adenosine deaminase Rattus norvegicus 15-34 8469375-1 1993 We determined whether 2"-deoxycoformycin (DCF), a potent highly specific inhibitor of adenosine deaminase (ADA), protected against transient forebrain ischemic neuronal injury in rat. Pentostatin 22-40 adenosine deaminase Rattus norvegicus 86-105 8249784-3 1993 We determined whether 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase, could mimic the effect of preconditioning in nonpreconditioned rats and potentiate the salutary effect of preconditioning in preconditioned rats. Pentostatin 22-40 adenosine deaminase Rattus norvegicus 70-89 8249784-3 1993 We determined whether 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase, could mimic the effect of preconditioning in nonpreconditioned rats and potentiate the salutary effect of preconditioning in preconditioned rats. Pentostatin 42-45 adenosine deaminase Rattus norvegicus 70-89 8469375-1 1993 We determined whether 2"-deoxycoformycin (DCF), a potent highly specific inhibitor of adenosine deaminase (ADA), protected against transient forebrain ischemic neuronal injury in rat. Pentostatin 22-40 adenosine deaminase Rattus norvegicus 107-110 8469375-1 1993 We determined whether 2"-deoxycoformycin (DCF), a potent highly specific inhibitor of adenosine deaminase (ADA), protected against transient forebrain ischemic neuronal injury in rat. Pentostatin 42-45 adenosine deaminase Rattus norvegicus 86-105 8469375-1 1993 We determined whether 2"-deoxycoformycin (DCF), a potent highly specific inhibitor of adenosine deaminase (ADA), protected against transient forebrain ischemic neuronal injury in rat. Pentostatin 42-45 adenosine deaminase Rattus norvegicus 107-110 1671090-0 1991 Brain adenosine and transmitter amino acid release from the ischemic rat cerebral cortex: effects of the adenosine deaminase inhibitor deoxycoformycin. Pentostatin 135-150 adenosine deaminase Rattus norvegicus 105-124 1611498-6 1992 Similar protection against focal ischemic brain damage was evident when the adenosine deaminase inhibitor, deoxycoformycin (500 micrograms/kg), was administered prior to the onset of ischemia. Pentostatin 107-122 adenosine deaminase Rattus norvegicus 76-95 1948767-1 1991 The developmental toxicity of the potent adenosine deaminase (ADA) inhibitor, pentostatin (2"-deoxycoformycin), was investigated in pregnant rats and rabbits administered daily iv doses during organogenesis. Pentostatin 78-89 adenosine deaminase Rattus norvegicus 41-60 1948767-1 1991 The developmental toxicity of the potent adenosine deaminase (ADA) inhibitor, pentostatin (2"-deoxycoformycin), was investigated in pregnant rats and rabbits administered daily iv doses during organogenesis. Pentostatin 78-89 adenosine deaminase Rattus norvegicus 62-65 1948767-1 1991 The developmental toxicity of the potent adenosine deaminase (ADA) inhibitor, pentostatin (2"-deoxycoformycin), was investigated in pregnant rats and rabbits administered daily iv doses during organogenesis. Pentostatin 91-109 adenosine deaminase Rattus norvegicus 62-65 1877368-4 1991 Inhibition of adenosine deaminase by deoxycoformycin produced a significant 1.4-fold increase in extracellular adenosine levels and a fall in inosine and hypoxanthine. Pentostatin 37-52 adenosine deaminase Rattus norvegicus 14-33 1318679-6 1992 Rats pretreated with the adenosine deaminase inhibitor deoxycoformycin excreted more ara-MAP and much less ara-H and allantoin. Pentostatin 55-70 adenosine deaminase Rattus norvegicus 25-44 1729390-0 1992 Rat brain adenosine deaminase after 2"-deoxycoformycin administration: biochemical properties and evidence for reduced enzyme levels detected by 2"-[3H]deoxycoformycin ligand binding. Pentostatin 36-54 adenosine deaminase Rattus norvegicus 10-29 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 113-131 adenosine deaminase Rattus norvegicus 31-50 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 113-131 adenosine deaminase Rattus norvegicus 52-55 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 113-131 adenosine deaminase Rattus norvegicus 99-102 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 133-136 adenosine deaminase Rattus norvegicus 31-50 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 133-136 adenosine deaminase Rattus norvegicus 52-55 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 133-136 adenosine deaminase Rattus norvegicus 99-102 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 287-290 adenosine deaminase Rattus norvegicus 31-50 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 287-290 adenosine deaminase Rattus norvegicus 52-55 1729390-1 1992 Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF. Pentostatin 287-290 adenosine deaminase Rattus norvegicus 99-102 1729390-2 1992 Here, we investigated the biochemical properties of ADA and the basis for its reduced activity after DCF treatment. Pentostatin 101-104 adenosine deaminase Rattus norvegicus 52-55 1729390-3 1992 It was found that much higher doses of DCF were required to inhibit ADA in DCF-treated compared with drug-naive animals. Pentostatin 39-42 adenosine deaminase Rattus norvegicus 68-71 1729390-3 1992 It was found that much higher doses of DCF were required to inhibit ADA in DCF-treated compared with drug-naive animals. Pentostatin 75-78 adenosine deaminase Rattus norvegicus 68-71 1729390-4 1992 Fourteen days after DCF administration, reduced ADA activity in brain homogenates was due to a decrease in Vmax, rather than to an altered Km of ADA for adenosine. Pentostatin 20-23 adenosine deaminase Rattus norvegicus 48-51 1729390-6 1992 The IC50 value for DCF inhibition of ADA in hypothalamus was unchanged. Pentostatin 19-22 adenosine deaminase Rattus norvegicus 37-40 1729390-7 1992 However, the Ki for DCF inhibition of ADA in whole brain increased by fivefold. Pentostatin 20-23 adenosine deaminase Rattus norvegicus 38-41 1729390-8 1992 Sucrose gradient analysis of brain ADA revealed only one corresponding peak of activity and [3H]DCF-labeled ADA in DCF-treated and control rats. Pentostatin 96-99 adenosine deaminase Rattus norvegicus 35-38 1729390-8 1992 Sucrose gradient analysis of brain ADA revealed only one corresponding peak of activity and [3H]DCF-labeled ADA in DCF-treated and control rats. Pentostatin 96-99 adenosine deaminase Rattus norvegicus 108-111 1729390-8 1992 Sucrose gradient analysis of brain ADA revealed only one corresponding peak of activity and [3H]DCF-labeled ADA in DCF-treated and control rats. Pentostatin 115-118 adenosine deaminase Rattus norvegicus 35-38 1729390-8 1992 Sucrose gradient analysis of brain ADA revealed only one corresponding peak of activity and [3H]DCF-labeled ADA in DCF-treated and control rats. Pentostatin 115-118 adenosine deaminase Rattus norvegicus 108-111 1729390-9 1992 A radioligand filtration assay with [3H]DCF was developed to assess the effects of DCF on ADA protein levels. Pentostatin 40-43 adenosine deaminase Rattus norvegicus 90-93 1441846-5 1992 The enzyme was inhibited by erythro-9-(2-hydroxy-3-nonyl)adenine and 2"-deoxycoformycin with Ki 4.4 x 10(-7) M and 3.2 x 10(-7) M for mitochondrial ADA and 4.9 x 10(-7) M 2.8 x 10(-7) M for cytosolic ADA. Pentostatin 69-87 adenosine deaminase Rattus norvegicus 148-151 1441846-5 1992 The enzyme was inhibited by erythro-9-(2-hydroxy-3-nonyl)adenine and 2"-deoxycoformycin with Ki 4.4 x 10(-7) M and 3.2 x 10(-7) M for mitochondrial ADA and 4.9 x 10(-7) M 2.8 x 10(-7) M for cytosolic ADA. Pentostatin 69-87 adenosine deaminase Rattus norvegicus 200-203 1671090-1 1991 The effects of a potent adenosine deaminase inhibitor, deoxycoformycin, on purine and amino acid neuro-transmitter release from the ischemic rat cerebral cortex were studied with the cortical cup technique. Pentostatin 55-70 adenosine deaminase Rattus norvegicus 24-43 2172653-9 1990 Two inhibitors of xanthine oxidase, allopurinol and oxypurinol, were also protective as was deoxycoformycin, an inhibitor of adenosine deaminase. Pentostatin 92-107 adenosine deaminase Rattus norvegicus 125-144 2825638-3 1987 These metabolic changes were suppressed in the presence of iodotubercidin (an inhibitor of adenosine kinase), but were reinforced in the presence of deoxycoformycin (an inhibitor of adenosine deaminase); 2-chloroadenosine induced no change in gluconeogenesis from lactate. Pentostatin 149-164 adenosine deaminase Rattus norvegicus 182-201 2179470-0 1990 2"-Deoxycoformycin inhibition of adenosine deaminase in rat brain: in vivo and in vitro analysis of specificity, potency, and enzyme recovery. Pentostatin 0-18 adenosine deaminase Rattus norvegicus 33-52 2179470-1 1990 2"-Deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), is increasingly used as a tool to investigate adenosine metabolism and neuromodulation. Pentostatin 0-18 adenosine deaminase Rattus norvegicus 48-67 2179470-1 1990 2"-Deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), is increasingly used as a tool to investigate adenosine metabolism and neuromodulation. Pentostatin 0-18 adenosine deaminase Rattus norvegicus 69-72 2179470-1 1990 2"-Deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), is increasingly used as a tool to investigate adenosine metabolism and neuromodulation. Pentostatin 20-23 adenosine deaminase Rattus norvegicus 48-67 2179470-1 1990 2"-Deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), is increasingly used as a tool to investigate adenosine metabolism and neuromodulation. Pentostatin 20-23 adenosine deaminase Rattus norvegicus 69-72 2179470-4 1990 In vivo, DCF inhibited ADA with ED50 values ranging from 155 to 280 micrograms/kg at 2 h posttreatment, and 98% inhibition was achieved with 1 mg/kg. Pentostatin 9-12 adenosine deaminase Rattus norvegicus 23-26 2179470-10 1990 The very low doses of DCF required for ADA inhibition in vivo are consistent with the high potency of this drug against ADA in vitro, and any physiological effects observed at low doses might therefore be ascribed to inhibition of ADA. Pentostatin 22-25 adenosine deaminase Rattus norvegicus 39-42 2179470-10 1990 The very low doses of DCF required for ADA inhibition in vivo are consistent with the high potency of this drug against ADA in vitro, and any physiological effects observed at low doses might therefore be ascribed to inhibition of ADA. Pentostatin 22-25 adenosine deaminase Rattus norvegicus 120-123 2179470-10 1990 The very low doses of DCF required for ADA inhibition in vivo are consistent with the high potency of this drug against ADA in vitro, and any physiological effects observed at low doses might therefore be ascribed to inhibition of ADA. Pentostatin 22-25 adenosine deaminase Rattus norvegicus 120-123 2572681-6 1989 Deoxycoformycin, an inhibitor of adenosine deaminase, failed to alter the levels of cyclic AMP or tyrosine hydroxylase activity. Pentostatin 0-15 adenosine deaminase Rattus norvegicus 33-52 3263396-4 1988 Inhibition of adenosine deaminase by 80% with the tight-binding inhibitor 2"-deoxycoformycin led to a 20% increase in the residual adenine nucleotide pool. Pentostatin 74-92 adenosine deaminase Rattus norvegicus 14-33 3262116-1 1988 The effects of the adenosine deaminase inhibitor, deoxycoformycin, on purine release from the rat cerebral cortex were studied with the cortical cup technique. Pentostatin 50-65 adenosine deaminase Rattus norvegicus 19-38 3499581-0 1987 Pharmacokinetics of 2"-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat. Pentostatin 20-38 adenosine deaminase Rattus norvegicus 56-75 3499581-1 1987 The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. Pentostatin 71-89 adenosine deaminase Rattus norvegicus 44-63 3499581-1 1987 The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. Pentostatin 71-89 adenosine deaminase Rattus norvegicus 65-68 3499581-1 1987 The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. Pentostatin 71-89 adenosine deaminase Rattus norvegicus 143-146 3499581-1 1987 The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. Pentostatin 91-94 adenosine deaminase Rattus norvegicus 44-63 3499581-1 1987 The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. Pentostatin 91-94 adenosine deaminase Rattus norvegicus 65-68 3499581-1 1987 The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. Pentostatin 91-94 adenosine deaminase Rattus norvegicus 143-146 3499581-5 1987 In brain, ADA was inhibited by about 95% at all three of these doses of DCF 2 hr after injection and activity returned to control levels by 30 days with the two smaller doses, but remained at 66% of control levels at 50 days with 18.6 mumol/kg. Pentostatin 72-75 adenosine deaminase Rattus norvegicus 10-13 6358608-0 1983 Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2"-deoxycoformycin. Pentostatin 119-137 adenosine deaminase Rattus norvegicus 60-79 3494649-6 1987 An involvement of adenosine in this response was demonstrated using an adenosine antagonist, caffeine, an uptake inhibitor, dipyridamole and an adenosine deaminase inhibitor, deoxycoformycin. Pentostatin 175-190 adenosine deaminase Rattus norvegicus 144-163 3515350-3 1986 2"-Deoxycoformycin was added to inhibit endogenous adenosine deaminase activity (maximal suppression was achieved at 0.8 microM concentration of the inhibitor). Pentostatin 0-18 adenosine deaminase Rattus norvegicus 51-70 3877709-1 1985 In rat lymph node lymphocytes stimulated for 24 h by concanavalin A in the presence of 10(-5) M 2"-deoxycoformycin (a potent inhibitor of adenosine deaminase) and 10(-5) M 2"-deoxyadenosine the adenylic nucleotide pool was reduced by 55.5% without modification of either the adenylic energy charge or the ability of the cells to liberate interleukin 2. Pentostatin 96-114 adenosine deaminase Rattus norvegicus 138-157 3877119-1 1985 Pentostatin (2"-deoxycoformycin), a potent inhibitor of adenosine deaminase, was administered therapeutically to rats with type II collagen-induced arthritis and the effects on hindpaw swelling, serum haptoglobin concentration, and anticollagen antibody titer determined. Pentostatin 0-11 adenosine deaminase Rattus norvegicus 56-75 3877119-1 1985 Pentostatin (2"-deoxycoformycin), a potent inhibitor of adenosine deaminase, was administered therapeutically to rats with type II collagen-induced arthritis and the effects on hindpaw swelling, serum haptoglobin concentration, and anticollagen antibody titer determined. Pentostatin 13-31 adenosine deaminase Rattus norvegicus 56-75 3485513-4 1986 Stable resistance to dCF is acquired in rat cells by overproduction of the enzyme adenosine deaminase (ADA) as a result of amplification of ADA gene sequences. Pentostatin 21-24 adenosine deaminase Rattus norvegicus 82-101 3485513-4 1986 Stable resistance to dCF is acquired in rat cells by overproduction of the enzyme adenosine deaminase (ADA) as a result of amplification of ADA gene sequences. Pentostatin 21-24 adenosine deaminase Rattus norvegicus 103-106 3485513-4 1986 Stable resistance to dCF is acquired in rat cells by overproduction of the enzyme adenosine deaminase (ADA) as a result of amplification of ADA gene sequences. Pentostatin 21-24 adenosine deaminase Rattus norvegicus 140-143 6605347-0 1983 Amplification of adenosine deaminase gene sequences in deoxycoformycin-resistant rat hepatoma cells. Pentostatin 55-70 adenosine deaminase Rattus norvegicus 17-36 6605347-1 1983 Deoxycoformycin-resistant rat hepatoma cells exhibit up to a 2000-fold increase in adenosine deaminase activity compared to the sensitive parental cells. Pentostatin 0-15 adenosine deaminase Rattus norvegicus 83-102 6605347-4 1983 Using this cDNA as a specific hybridization probe, all deoxycoformycin-resistant variants were shown to have increased amounts of adenosine deaminase mRNA and gene sequences. Pentostatin 55-70 adenosine deaminase Rattus norvegicus 130-149 6605347-6 1983 However, the degree of adenosine deaminase gene amplification in one deoxycoformycin-resistant cell line (6-10-200) was 3-4-fold less than the relative increase in adenosine deaminase mRNA. Pentostatin 69-84 adenosine deaminase Rattus norvegicus 23-42 6605347-7 1983 These results indicate that the increased adenosine deaminase activity in deoxycoformycin-resistant rat hepatoma cells is due in large part, but not exclusively, to gene amplification. Pentostatin 74-89 adenosine deaminase Rattus norvegicus 42-61 6604525-1 1983 Rat polymorphonuclear leucocytes or neonatal-rat heart cells in culture were treated with 2"-deoxycoformycin and 5-iodotubercidin at concentrations that inhibited adenosine deaminase (EC 3.5.4.4) and adenosine kinase (EC 2.7.1.20) inside the intact cells, and the rate of adenosine accumulation was determined. Pentostatin 90-108 adenosine deaminase Rattus norvegicus 163-182 6358608-1 1983 2"-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent. Pentostatin 0-18 adenosine deaminase Rattus norvegicus 50-69 6358608-1 1983 2"-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent. Pentostatin 0-18 adenosine deaminase Rattus norvegicus 71-74 6358608-1 1983 2"-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent. Pentostatin 20-23 adenosine deaminase Rattus norvegicus 50-69 6358608-1 1983 2"-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent. Pentostatin 20-23 adenosine deaminase Rattus norvegicus 71-74 6358608-2 1983 In this study the kinetics of ADA expression was assessed by immunomorphologic and enzymatic methods in tissues of ACI rats given injections of DCF. Pentostatin 144-147 adenosine deaminase Rattus norvegicus 30-33 6259294-2 1981 2"-Deoxycoformycin (2"-DCF), an adenosine deaminase inhibitor, slightly increased basal, adenosine, and norepinephrine-elicited accumulations of cyclic AMP, whereas dipyridamole, an uptake inhibitor, had an even greater effect on cyclic AMP accumulations under the same conditions. Pentostatin 0-18 adenosine deaminase Rattus norvegicus 32-51 6259294-2 1981 2"-Deoxycoformycin (2"-DCF), an adenosine deaminase inhibitor, slightly increased basal, adenosine, and norepinephrine-elicited accumulations of cyclic AMP, whereas dipyridamole, an uptake inhibitor, had an even greater effect on cyclic AMP accumulations under the same conditions. Pentostatin 20-26 adenosine deaminase Rattus norvegicus 32-51 6249264-8 1980 Pentostatin (30 microM), a specific inhibitor of adenosine deaminase, completely inhibited hypoxanthine production from exogenous adenosine (55 microM), but did not black CN-induced hypoxanthine production or cause adenosine accumulation in intact cells. Pentostatin 0-11 adenosine deaminase Rattus norvegicus 49-68 231980-10 1979 The effects of inosine, or adenosine along with an inhibitor of adenosine deaminase (pentostatin) suggest that adenosine acts on the glucose consumption through adenylic nucleotides. Pentostatin 85-96 adenosine deaminase Rattus norvegicus 64-83 6600234-0 1983 Increased adenosine deaminase synthesis and messenger RNA activity in deoxycoformycin-resistant cells. Pentostatin 70-85 adenosine deaminase Rattus norvegicus 10-29 6600234-1 1983 The basis for the increased adenosine deaminase activity in deoxycoformycin-resistant rat hepatoma cells was investigated. Pentostatin 60-75 adenosine deaminase Rattus norvegicus 28-47 6815190-0 1982 Adenosine deaminase from deoxycoformycin-sensitive and -resistant rat hepatoma cells. Pentostatin 25-40 adenosine deaminase Rattus norvegicus 0-19 6815190-2 1982 Deoxycoformycin-resistant rat hepatoma cells exhibit up to 300-fold increase in adenosine deaminase activity compared to the sensitive parental cells. Pentostatin 0-15 adenosine deaminase Rattus norvegicus 80-99 6815190-3 1982 In order to determine the basis of the increased enzyme activity in deoxycoformycin-resistant cells, adenosine deaminase was purified from rat liver and deoxycoformycin-sensitive and -resistant cells. Pentostatin 68-83 adenosine deaminase Rattus norvegicus 101-120 6815190-3 1982 In order to determine the basis of the increased enzyme activity in deoxycoformycin-resistant cells, adenosine deaminase was purified from rat liver and deoxycoformycin-sensitive and -resistant cells. Pentostatin 153-168 adenosine deaminase Rattus norvegicus 101-120 6815190-9 1982 These data indicate that deoxycoformycin-resistant rat hepatoma cells produce increased amounts of adenosine deaminase protein which results in increased enzymatic activity. Pentostatin 25-40 adenosine deaminase Rattus norvegicus 99-118